Format
Deal Terms Analysis
2024 M&A Deal Terms Study
Deal Terms Analysis
2024 M&A Working Capital PPA Study
Deal Terms Analysis
Why Are M&A Deal Parties Thinking Twice About RWI?
Deal Terms Analysis
M&A Earnouts: Be Prepared for 2024
Deal Terms Analysis
M&A Deal Terms: Three Trends to Watch in 2024
Shareholder Representation
Deal Terms Analysis
M&A Purchase Price Adjustments Are Common Yet Complex
Deal Terms Analysis
Valuation Disconnects Driving a Spike in Earnouts in M&A
Deal Terms Analysis
Lower Middle-Market Mergers & Acquisitions Deals Report
Deal Terms Analysis
Life Sciences
2023 SRS Acquiom Life Sciences M&A Study
Deal Terms Analysis
2023 M&A Deal Terms and Trends for Private Equity Buyers
Deal Terms Analysis
Technology M&A Deal Terms and Trends
Deal Terms Analysis
Indemnification
Effect of Representations and Warranties Insurance on Deal Terms
Deal Terms Analysis
Due Diligence
Private M&A Deal Terms: An SRS Acquiom Quick Guide for M&A Advisors
Deal Terms Analysis
Tools and Tactics for Getting Deals Across the Finish Line
Deal Terms Analysis
Indemnification
Deal Terms for M&A Escrows - Statistics and Key Findings
Deal Terms Analysis
2023 M&A Deal Terms Study
Deal Terms Analysis
M&A Trends: PPAs and Claims Activity
Deal Terms Analysis
Post-Closing M&A Claims and Purchase Price Adjustments: Where Do They Stand Heading Into 2023?
Deal Terms Analysis
2022 PE-Buyer Deal Terms
Deal Terms Analysis
Due Diligence
How M&A Advisors Use Deal Data to Improve the Due Diligence Process
Deal Terms Analysis
2022 M&A Deal Terms Study Update with Key Findings
Deal Terms Analysis
Indemnification
2022 M&A Claims Insights Report
Deal Terms Analysis
2022 Technology M&A Deals Special Report
Deal Terms Analysis
2022 M&A Deal Terms Study
Deal Terms Analysis
2021 Life Sciences M&A Study
Deal Terms Analysis
Shareholder Representation
2021 M&A Deal Terms Study Key Findings
Deal Terms Analysis
2021 M&A Deal Terms Study
Deal Terms Analysis
2020 M&A Claims Insights Report
Deal Terms Analysis
Shareholder Representation
What to Make of the Great Hill Case – The M&A Bar is Not Yet in Agreement on How Best to Address Merger Agreement Privilege Issues
Deal Terms Analysis
2020 Review: COVID-19 Impact on M&A Transactions
Deal Terms Analysis
M&A Deal Terms & Trends Pre- & Post-COVID-19
Deal Terms Analysis
Shareholder Representation
M&A: Who Owns the Attorney-Client Privilege After Closing?
Deal Terms Analysis
2020 Buy-Side Reps and Warranties Insurance Deal Terms Update
Deal Terms Analysis
A First Look at the Impacts of Coronavirus on M&A Transactions
Deal Terms Analysis
Life Sciences
Life Sciences: Milestone Trends by Product Stage
Deal Terms Analysis
Life Sciences
Life Sciences: Timeline of Milestone Payments
Deal Terms Analysis
Shareholder Representation
Addressing Target Company Privilege in Merger Agreements Five Years after Great Hill v. SIG
Life Sciences
Deal Terms Analysis
Shareholder Representation
Life Sciences M&A: Private Target Deal Trends
Deal Terms Analysis
Shareholder Representation
Beware of Exclusions When Defining Net Working Capital in M&A Transactions
Deal Terms Analysis
Life Sciences
2019 Life Sciences Study Quick Reference Guide
Deal Terms Analysis
Life Sciences
2019 Life Sciences M&A Study
Deal Terms Analysis
2018 M&A Claims Insights Report
Deal Terms Analysis
Shareholder Representation
Understanding Changes in Shareholder Consent Requirements
Deal Terms Analysis
Shareholder Representation
Impact of “Buyer Power Ratio” on M&A Deal Terms
Deal Terms Analysis
Shareholder Representation
Clarifying When Attorneys’ Fees Constitute Damages
Deal Terms Analysis
Shareholder Representation
M&A Conflict Waivers
Deal Terms Analysis
Shareholder Representation
Do Carveouts to Caps Work the Way You Intend?
Deal Terms Analysis
Shareholder Representation
Definition of Purchase Price